Positive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 3/by MaxUPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Clinical Trial: JSB462 (Luxdegalutamide) in Combination With Abiraterone for mHSPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by Max177Lu-PSMA-I&T Results in First Prospective Study
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxNewsletter 21/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! As you may have noticed, I have started writing about the research results that will be presented at ASCO 2025. And I still have many more to review and write about! I had to condense the information in this […]
Single-Cell RNA Sequencing Reveals Three Immune Archetypes in Bone Metastases Across Multiple Cancer Types
/0 Comments/in Immunotherapy, mRNA, Preclinical Research/by MaxPhase 3 ENZAMET Trial: Follow-up Data After 8 Years
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- New Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models August 9, 2025
- Phase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC) August 8, 2025
- Phase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC August 8, 2025
- Phase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC August 8, 2025